Subscribe

Keytruda Receives New Indication for Metastatic Small-Cell Lung Cancer After Disease Progression

August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - FDA Approvals

On June 17, 2019, the FDA granted accelerated approval to pembrolizumab (Keytruda; Merck) monotherapy for the treatment of patients with metastatic small-cell lung cancer whose disease progressed during or after platinum-based chemotherapy and at least 1 previous therapy. The FDA granted this application a priority review, making it the fifth FDA approval this year for pembrolizumab.

This new indication was based on data from 83 patients with small-cell lung cancer whose disease progressed during or after ≥2 previous therapies and were enrolled in the multicenter, nonrandomized, open-label KEYNOTE-158 or KEYNOTE-028 clinical trials.

Treatment with pembrolizumab continued until disease progression, unacceptable toxicity, or a maximum of 24 months. Overall response rate (ORR) and duration of response were the primary end points.

The ORR was 19% (95% confidence interval, 11-29), including 2% complete responses and 17% partial responses. Of the 16 responding patients, 15 (94%) sustained a response for ≥6 months. The responses were durable for ≥12 months in 10 (63%) patients and for ≥18 months in 9 (56%) patients.

The safety profile in this study was similar to that seen in other studies with pembrolizumab monotherapy. A total of 9% of patients discontinued treatment because of adverse events, and 25% of the patients had at least 1 dose of pembrolizumab withheld because of an adverse reaction. Serious adverse events were reported in 31% of patients, most often (≥2%) pneumonia and pleural effusion.

Related Items
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
Web Exclusives published on June 19, 2020 in FDA Approvals, Lung Cancer
Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma
Web Exclusives published on June 19, 2020 in FDA Approvals
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Web Exclusives published on June 8, 2020 in FDA Approvals, Lung Cancer
Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Web Exclusives published on June 1, 2020 in FDA Approvals, Lung Cancer
Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma
Web Exclusives published on June 1, 2020 in FDA Approvals, Lung Cancer
Last modified: August 16, 2019
Copyright © Engage Healthcare Communications, LLC. All rights reserved.